Cargando…

Paying Physicians to Prescribe Generic Drugs and Follow-On Biologics in the United States

Aaron Kesselheim and colleagues examine potential strategies to promote greater prescribing of generic drugs and follow-on biologics

Detalles Bibliográficos
Autores principales:	Sarpatwari, Ameet, Choudhry, Niteesh K., Avorn, Jerry, Kesselheim, Aaron S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Policy Forum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4363899/ https://www.ncbi.nlm.nih.gov/pubmed/25781468 http://dx.doi.org/10.1371/journal.pmed.1001802

Ejemplares similares

Analysis of risk evaluation and mitigation strategies for teratogenic drugs: Variation in primary and secondary prevention measures
por: Brown, Beatrice L., et al.
Publicado: (2023)

Regulatory Solutions to the Problem of High Generic Drug Costs
por: Luo, Jing, et al.
Publicado: (2015)

The Case for Reforming Drug Naming: Should Brand Name Trademark Protections Expire upon Generic Entry?
por: Sarpatwari, Ameet, et al.
Publicado: (2016)

Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage
por: Kesselheim, Aaron S., et al.
Publicado: (2017)

An Uninformative Truth: The Logic of Amarin’s Off-Label Promotion
por: Hey, Spencer Phillips, et al.
Publicado: (2016)

Who Should Pay for Global Health, and How Much?
por: Carrasco, Luis R., et al.
Publicado: (2013)

Postmarket Surveillance of Medical Devices: A Comparison of Strategies in the US, EU, Japan, and China
por: Kramer, Daniel B., et al.
Publicado: (2013)

The effect of federal and state off-label marketing investigations on drug prescribing: The case of olanzapine
por: Wang, Bo, et al.
Publicado: (2017)

US public investment in development of mRNA covid-19 vaccines: retrospective cohort study
por: Lalani, Hussain S, et al.
Publicado: (2023)

The state of the antivaccine movement in the United States: A focused examination of nonmedical exemptions in states and counties
por: Olive, Jacqueline K., et al.
Publicado: (2018)

A National Health Insurance Program for the United States
por: McCanne, Don R
Publicado: (2004)

Ghostwriting at Elite Academic Medical Centers in the United States
por: Lacasse, Jeffrey R., et al.
Publicado: (2010)

Evidence-Based Prescribing of Statins: A Developing World Perspective
por: Ong, H. T
Publicado: (2006)

Physicians’ Trust in the FDA’s Use of Product-Specific Pathways for Generic Drug Approval
por: Kesselheim, Aaron S., et al.
Publicado: (2016)

Public sector financial support for late stage discovery of new drugs in the United States: cohort study
por: Nayak, Rahul K, et al.
Publicado: (2019)

Biocrimes, Microbial Forensics, and the Physician
por: Schutzer, Steven E, et al.
Publicado: (2005)

Left to Their Own Devices: Breakdowns in United States Medical Device Premarket Review
por: Hines, Jonas Zajac, et al.
Publicado: (2010)

Stigma as a fundamental hindrance to the United States opioid overdose crisis response
por: Tsai, Alexander C., et al.
Publicado: (2019)

The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United States
por: Gagnon, Marc-André, et al.
Publicado: (2008)

Characteristics of US Patients and Prescribers Using Hydroxychloroquine During the COVID-19 Pandemic
por: Rome, Benjamin N., et al.
Publicado: (2021)

Moving Beyond “Food Deserts”: Reorienting United States Policies to Reduce Disparities in Diet Quality
por: Block, Jason P., et al.
Publicado: (2015)

Male Circumcision for Prevention of HIV Transmission: What the New Data Mean for HIV Prevention in the United States
por: Sullivan, Patrick S, et al.
Publicado: (2007)

Call to Action: Promoting Domestic and Global Tobacco Control by Ratifying the Framework Convention on Tobacco Control in the United States
por: Mackey, Tim K., et al.
Publicado: (2014)

Addressing disparities in the health of persons with HIV attributable to unstable housing in the United States: The role of the Ryan White HIV/AIDS Program
por: Griffin, Amy, et al.
Publicado: (2020)

Involuntary mental health treatment in the era of the United Nations Convention on the Rights of Persons with Disabilities
por: Mahomed, Faraaz, et al.
Publicado: (2018)

Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study
por: Desai, Rishi J, et al.
Publicado: (2018)

Human Rights Research and Ethics Review: Protecting Individuals or Protecting the State?
por: Amon, Joseph J., et al.
Publicado: (2012)

A Comprehensive Framework for Human Resources for Health System Development in Fragile and Post-Conflict States
por: Fujita, Noriko, et al.
Publicado: (2011)

Use of Extrapolation in New Drug Approvals by the US Food and Drug Administration
por: Feldman, Daniel, et al.
Publicado: (2022)

Competition law and pricing among biologic drugs: the case of VEGF therapy for retinal diseases
por: Van de Wiele, Victor L, et al.
Publicado: (2022)

Variation in Use of Lung Cancer Targeted Therapies Across State Medicaid Programs, 2020-2021
por: Roberts, Thomas J., et al.
Publicado: (2023)

Physician experiences with and perceptions of risk evaluation and mitigation strategy programs with elements to assure safe use
por: Sarpatwari, Ameet, et al.
Publicado: (2023)

Evolution of drug regulations and regulatory innovation for anticancer drugs in China
por: Liu, Yang, et al.
Publicado: (2022)

Competition and price among brand-name drugs in the same class: A systematic review of the evidence
por: Sarpatwari, Ameet, et al.
Publicado: (2019)

Educating a New Generation of Doctors to Improve the Health of Populations in Low- and Middle-Income Countries
por: Celletti, Francesca, et al.
Publicado: (2011)

New era of drug innovation in China
por: Ye, Xuan, et al.
Publicado: (2019)

Cholinesterase Inhibitors: Drugs Looking for a Disease?
por: Maggini, Marina, et al.
Publicado: (2006)

New Approaches to Filling the Gap in Tuberculosis Drug Discovery
por: Casenghi, Martina, et al.
Publicado: (2007)

Market Failure and the Poverty of New Drugs in Maternal Health
por: Fisk, Nicholas M, et al.
Publicado: (2008)

Global Pharmacovigilance for Antiretroviral Drugs: Overcoming Contrasting Priorities
por: Bakare, Nyasha, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_nsbimj2e9cj34lm9ea8sqkjh62